Search PubMedSearch

PubMed · 332002

Irreversible curarization.

Abstract

The reversal effect of neostigmine following different doses of tubocurarine was investigated in 20 anesthetized adults. After five minutes, neostigmine could rapidly and effectively reverse a blocking dose of tubocurarine. Doubling the dose of tubocurarine necessitated a much higher concentration of neostigmine to achieve reversal, while a triple dose could be reversed only after enough time had elapsed to allow for lowering its concentration. It is concluded that the degree of reversal by neostigmine is related inversely to the concentration of tubocurarine at the time of reversal. An overdose of tubocurarine predisposes to the so called "neostigmine-resistant curarization".

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Baraka. 1977. Irreversible curarization.. https://doi.org/10.1177/0310057x7700500311

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer.

Difluoromethylornithine (DFMO) is a promising chemopreventive agent which is excreted unchanged in the urine, is active in vivo against superficial bladder cancer in animal tumor model systems, and has cytotoxic activity in vitro against superficial bladder cancer cells. Thus, DFMO may be particularly efficacious in preventing the development of bladder tumors and/or for the therapy of established superficial bladder cancer. To examine this hypothesis, an intergroup clinical trial is currently accruing patients with cystoscopically resected superficial bladder cancer (who would otherwise simply be observed). While the primary goal of this protocol is to define a daily dose of DFMO having little or no toxicity for use in future randomized chemoprevention trials, the rate of recurrent bladder tumors will also be followed in the hope that DFMO will inhibit the development of recurrent bladder cancers.

Clinical Trials as Topic